Ozempic, Blood Pressure and Cholesterol: What the Cardiometabolic Trials Found

The question tends to arrive in a hopeful half-whisper: my pressure has been lower since I started the shot, so can I come off the pill now? Since late 2023, when the SELECT trial reported fewer heart attacks and strokes in people taking semaglutide, searches for ozempic and blood pressure have climbed in step with prescriptions, and that question is being asked in a lot of exam rooms.

As of September 2026 the interest shows no sign of cooling. Regulators have added heart and kidney wording to semaglutide labels, follow-up analyses from the big trials keep appearing in journals, and social feeds are full of posts claiming the medicine quietly fixes cholesterol as a bonus. Some of that is grounded in solid data. Some of it is a stretch.

This explainer stays close to what the cardiometabolic trials measured: how far blood pressure actually moved, what happened to LDL cholesterol and triglycerides, who was studied, and where the evidence thins out. Numbers first, enthusiasm second.

What changed recently with Ozempic, blood pressure and heart risk?

Three dates explain the current wave of attention. The first is September 2016, when the SUSTAIN-6 trial, a randomized study of 3,297 adults with type 2 diabetes, reported that semaglutide lowered the combined rate of cardiovascular death, heart attack and stroke by about 26 percent over roughly two years. That result led the US Food and Drug Administration to add a cardiovascular risk-reduction indication to the Ozempic label in January 2020, limited to adults with type 2 diabetes and established heart disease.

The second is November 2023, when the SELECT trial was published. It enrolled 17,604 adults who had heart disease and overweight or obesity but no diabetes, and it tested the higher-strength semaglutide product sold as Wegovy. Major cardiovascular events fell by 20 percent. In March 2024 the FDA approved Wegovy to reduce heart-attack and stroke risk in that group, the first time a weight-management medicine had earned such wording.

The third is January 2025, when the FDA expanded Ozempic’s label to cover slowing kidney disease in adults with type 2 diabetes, based on the FLOW trial, which was stopped early because the benefit was already clear. Kidney function and blood pressure are tightly linked, so that news pulled blood pressure back into the conversation.

Layered on top is a steady stream of secondary analyses from these trials examining blood pressure, inflammation markers and lipids, each one generating headlines. The medicine itself has not changed. What has changed is how much is known about who it helps and what it does beyond glucose, and the widening gap between those careful findings and the broader claims circulating online.

What is Ozempic, and how does a GLP-1 medicine reach the heart and vessels?

Ozempic is the brand name of an injectable form of semaglutide approved for adults with type 2 diabetes. Semaglutide belongs to a class called GLP-1 receptor agonists: medicines that mimic glucagon-like peptide-1, a hormone the gut releases after meals to prompt insulin, dampen glucagon, slow stomach emptying and signal fullness to the brain.

That sounds like a glucose story, and for the first decade it mostly was. Yet GLP-1 receptors are not confined to the pancreas. They sit on cells in the kidney, on the lining of blood vessels, in the heart’s upper chambers and in brain regions that govern appetite and the autonomic nervous system, the part of the nervous system that runs heart rate and vessel tone without conscious input.

How, then, could a medicine built for blood sugar touch blood pressure? Researchers describe three overlapping routes. The indirect route is weight: carrying less tissue reduces the pumping load and quiets several hormonal systems that raise pressure. The kidney route is natriuresis, a term for the kidney releasing more sodium into the urine, which lowers fluid volume. The vascular route is reduced inflammation and improved function of the endothelium, the thin inner lining of arteries that helps them relax.

Which route dominates in people is still debated, and the honest answer is that the trials were not designed to separate them. What they were designed to do was track outcomes: readings, lab values and, in the largest studies, actual heart attacks and strokes. The sections that follow stay close to those measurements, because that is where the evidence is firmest.

Does Ozempic lower blood pressure? What the randomized trials measured

Blood pressure is written as two numbers: systolic, the pressure when the heart contracts, and diastolic, the pressure between beats. In the semaglutide trials, the movement was almost entirely in the systolic figure.

SUSTAIN-6, the diabetes outcome trial behind Ozempic’s heart indication, recorded systolic reductions of roughly 1–3 mmHg compared with placebo across its two treatment groups. Diastolic pressure barely budged. Participants began the study with pressure that was already being treated and averaged in the mid-130s systolic, which leaves less room to fall.

The STEP program, which tested the higher-strength formulation in people with overweight or obesity, saw larger shifts. In STEP 1, systolic pressure dropped about 6 mmHg from baseline over 68 weeks, against roughly 1 mmHg in the placebo group, a net difference near 5 mmHg. SELECT, with its 17,604 participants, reported a placebo-adjusted systolic reduction of about 3.8 mmHg at two years.

Two patterns recur. People who lose more weight generally show larger drops, although the relationship is not one-to-one. And those who start with higher pressure tend to fall further, which is typical of any intervention that touches blood pressure. The trials also enrolled many people already taking antihypertensive medicines, so the measured effect sits on top of existing treatment rather than replacing it.

So the answer to the search question is yes, with a qualifier. Ozempic and blood pressure move together in the trial data, in a downward direction, by an amount that is real but modest. Whether that amount matters for an individual depends on where they started and what else they are doing.

How does the blood pressure effect compare with lifestyle changes and medicines?

Numbers mean more with company. A 3–5 mmHg systolic reduction is close to what trials of regular aerobic exercise produce, and roughly what cutting dietary sodium achieves in people with hypertension. The DASH eating pattern, rich in vegetables, fruit, low-fat dairy and whole grains, lowers systolic pressure by up to about 11 mmHg in people with high blood pressure, according to Mayo Clinic’s summary of the lifestyle evidence. A single antihypertensive medicine typically lowers systolic pressure by around 9 mmHg.

Seen that way, semaglutide is not a blood pressure medicine with a weight side effect; it is a weight and glucose medicine with a blood pressure side benefit of lifestyle-change size.

Even so, population-level data give that size some weight. A 2021 pooled analysis of 48 blood-pressure-lowering trials, covering more than 340,000 people, found that each 5 mmHg reduction in systolic pressure was associated with roughly 10 percent fewer major cardiovascular events, whatever the starting pressure. Nobody can claim that semaglutide’s blood pressure effect alone produced the outcome benefits seen in SELECT; the trial was not built to test that. It does mean the shift lands in a range that epidemiology treats as meaningful.

Durability is the other question readers ask. In the two-year SELECT data, the reduction held while people stayed on treatment. Observational reports suggest weight and blood pressure drift back after the medicine stops, which is consistent with an effect that depends on continued use. There is no good trial evidence that semaglutide resets blood pressure permanently.

For an individual reader, the practical message is that home readings may improve, sometimes noticeably, and that this is a conversation to have with the clinician who manages those readings, never a reason to adjust tablets independently.

Ozempic and cholesterol: what happened to LDL, triglycerides and HDL?

Here the viral claims run furthest ahead of the data. LDL cholesterol, the so-called bad cholesterol, is the particle most directly tied to plaque in artery walls. Triglycerides are the fats the body stores and transports after eating. HDL is the particle involved in carrying cholesterol back to the liver.

In STEP 1, total cholesterol and LDL fell by about 3 percent more than placebo. That is a genuine change in a statistical sense and a negligible one in a clinical sense; a statin, the standard class of cholesterol-lowering medicine, typically lowers LDL by 30–50 percent. SELECT showed a similarly small relative LDL reduction, in the low single digits.

Triglycerides tell a different story. STEP 1 reported a relative reduction of about 22 percent, and SELECT found a reduction near 18 percent compared with placebo. Those are sizeable shifts, in line with what substantial weight loss and better glucose control produce by other means, because excess calories and insulin resistance drive triglyceride production in the liver.

HDL rose slightly, typically by a few percent, which again tracks weight loss and is of uncertain clinical significance on its own.

One lipid-adjacent marker did move dramatically. High-sensitivity C-reactive protein (hsCRP), a blood test for low-grade inflammation, fell by roughly 38 percent relative to placebo in SELECT, a change visible within weeks and larger than the weight loss alone would predict. Inflammation is now understood as a contributor to plaque instability, so researchers have paid attention.

The honest summary of ozempic and cholesterol: strong effect on triglycerides, trivial effect on LDL, intriguing effect on inflammation. Anyone told that the medicine handles cholesterol should hear that LDL, the number guidelines target hardest, is not where it works.

Did Ozempic reduce heart attacks and strokes in the outcome trials?

Blood pressure and cholesterol are surrogate markers: measurements that stand in for the outcomes patients actually care about. The strongest evidence comes from trials that counted those outcomes directly.

SUSTAIN-6 randomized 3,297 adults with type 2 diabetes, most of whom already had cardiovascular disease, to semaglutide or placebo for about two years. The primary endpoint was major adverse cardiovascular events (MACE), a composite of cardiovascular death, nonfatal heart attack and nonfatal stroke. MACE occurred in 6.6 percent of the semaglutide group versus 8.9 percent on placebo, a 26 percent relative reduction. The result was driven mostly by fewer strokes; cardiovascular death did not differ. The trial was designed to show the medicine was not harmful to the heart, so the benefit was a welcome surprise rather than a pre-specified target.

SELECT was built to test benefit. Its 17,604 participants, aged 45 and over with a prior heart attack, stroke or peripheral artery disease plus overweight or obesity, were followed for a mean of about 3.3 years. MACE occurred in 6.5 percent on semaglutide versus 8.0 percent on placebo, a 20 percent relative reduction, with heart attack the component that fell most clearly. Weight loss averaged about 9 percent versus under 1 percent on placebo.

Those percentages deserve translation. In SELECT, roughly 1.5 fewer people in every 100 had a major event over three years. The absolute figure is modest and the relative figure is impressive; both are true. For context, the benefit sits in similar territory to statins used after a first cardiac event.

Neither trial enrolled people without heart disease, and neither tested people with diabetes or obesity but no cardiovascular history in a dedicated outcome study. Those gaps shape what can honestly be said next.

Semaglutide trials at a glance: blood pressure, lipids and heart outcomes

Four randomized, placebo-controlled trials carry most of the weight in this story. Laid side by side, they show the same direction of travel in different populations, which is itself a form of evidence. Figures are approximate and drawn from the published primary reports and their secondary analyses.

Trial (year)	Who was studied	Systolic BP vs placebo	Lipid findings	Heart outcome
SUSTAIN-6 (2016)	3,297 adults with type 2 diabetes, most with heart disease	About 1–3 mmHg lower	Minor changes	MACE 26% lower, mainly fewer strokes
STEP 1 (2021)	1,961 adults with overweight or obesity, no diabetes	About 5 mmHg lower	Triglycerides down about 22%; LDL down about 3%	Not designed to measure events
SELECT (2023)	17,604 adults with heart disease and overweight or obesity, no diabetes	About 3.8 mmHg lower	Triglycerides down about 18%; LDL down low single digits; hsCRP down about 38%	MACE 20% lower, mainly fewer heart attacks
FLOW (2024)	3,533 adults with type 2 diabetes and chronic kidney disease	Modest reduction reported	Not a primary focus	Kidney events 24% lower; MACE 18% lower

Two caveats belong next to the table. STEP 1 and SELECT used the higher-strength formulation marketed as Wegovy, while SUSTAIN-6 and FLOW used the strengths sold as Ozempic, so the rows are not interchangeable. And all four trials were funded by the manufacturer, which is standard for drug-approval studies but is one reason independent secondary analyses matter.

What the table makes plain is that the blood pressure figure is consistent and small, the triglyceride figure is consistent and larger, and the event reduction appears wherever cardiovascular or kidney disease was already present. That last pattern, not the blood pressure number, is the headline finding.

What the evidence actually says: grading the strength

Not every finding in this story deserves the same confidence. Sorting them by the kind of evidence behind them is the fairest way to read it.

Strong evidence (large randomized, blinded trials): semaglutide reduces major cardiovascular events in adults with type 2 diabetes and established heart disease, and in adults with heart disease plus overweight or obesity. It produces a modest systolic blood pressure reduction of a few mmHg and a substantial fall in triglycerides. These results come from tens of thousands of participants followed for years, with hard endpoints adjudicated by independent committees.

Moderate evidence (randomized trials, secondary or kidney endpoints): the reduction in hsCRP, the slowing of kidney disease in FLOW, and the small HDL rise. Real, but either measured as secondary outcomes or in a single trial.

Weak or uncertain evidence (post hoc analyses, observational data, mechanism studies): the idea that the heart benefit is independent of weight loss; the assumption that benefit extends to people without heart disease; the belief that blood pressure stays down after stopping. Each is plausible. None has a trial designed to prove it.

Evidence against the claim: that semaglutide meaningfully lowers LDL cholesterol. The trials measured it and found changes of a few percent.

Two further honesty notes. Around one in six SELECT participants on semaglutide stopped the medicine, most often for gastrointestinal reasons, so the real-world population that stays on treatment may differ from the trial average. And the trials excluded people with recent heart attacks, severe kidney failure and several other conditions, so their results describe the people enrolled, not everyone who might be prescribed the medicine. Guideline committees weigh exactly these gaps when they decide how firmly to recommend something, and readers can borrow the same habit.

Is the heart benefit just weight loss, or something more?

This is the most interesting open question in cardiometabolic medicine right now, and it is worth being clear that it remains open.

The case for something more rests on timing and pattern. In SELECT, the event curves for semaglutide and placebo began to separate within the first few months, before most participants had lost much weight. The drop in hsCRP, the inflammation marker, was also visible early and was larger than the amount of weight lost would predict. A secondary analysis found the relative reduction in events was broadly similar whether people started with a body mass index in the overweight range or well into the obesity range, and did not track neatly with how much weight each person lost.

The case for caution is methodological. Those observations come from analyses planned after the main result was in, which can detect patterns but cannot prove them. People who lose weight on a medicine may differ in other ways from those who do not. And the trial compared semaglutide with placebo, not with an equal amount of weight loss achieved another way, so it cannot say what weight loss alone would have delivered.

Laboratory and animal studies offer mechanisms: GLP-1 receptors on vessel walls, effects on plaque inflammation, changes in kidney sodium handling. Human trials measuring plaque directly are small so far.

Where does that leave a reader? At the level of expert opinion. Most cardiologists who study this suspect a mix of weight-driven and direct effects, with the proportions unknown. For practical purposes the distinction matters less than it seems. The outcome benefit was measured in real people with real events, and it was measured in those who already had cardiovascular disease. That is the population the evidence speaks to, whichever mechanism turns out to carry the load.

Heart rate and other cardiometabolic side effects to know about

A medicine that lowers blood pressure a little also raises resting heart rate a little, and the two effects arrive together. Across the semaglutide trials, resting pulse rose by roughly 2–4 beats per minute compared with placebo. The mechanism is not fully understood; direct action on the heart’s pacemaker cells and shifts in autonomic balance have both been proposed. In SUSTAIN-6 and SELECT the increase was not linked to more cardiac events, but it is the reason clinicians sometimes ask about palpitations at follow-up.

The most common side effects are gastrointestinal: nausea, vomiting, diarrhea and constipation, especially early in treatment. These usually ease, but when vomiting is persistent it can cause dehydration, which in turn can drop blood pressure, cause dizziness on standing and stress the kidneys. People who also take diuretics or certain blood pressure medicines are more exposed to that chain of events.

Less common effects reported in trials and labels include gallbladder problems such as gallstones, inflammation of the pancreas (pancreatitis), and, in SUSTAIN-6, a higher rate of diabetic retinopathy complications in people whose glucose fell quickly. Low blood sugar is uncommon with semaglutide alone but becomes more likely when it is combined with insulin or a sulfonylurea.

The prescribing information also carries a boxed warning about thyroid C-cell tumors, based on rodent studies; it is not known whether the risk applies to people, and the medicine is not used in anyone with a personal or family history of medullary thyroid cancer or a related genetic syndrome.

None of this is a reason for alarm, and the outcome trials show that for the populations studied the benefits outweighed these risks. It is a reason for monitoring, which is exactly what the prescribing clinician does. The section on when to see a doctor below translates these effects into specific warning signs.

Ozempic vs Wegovy: same molecule, different trials and approvals

Readers can be forgiven for mixing up the two names, because the molecule is identical. The difference lies in the strengths available, the populations studied and, as a result, what each label is permitted to say.

Ozempic is approved for adults with type 2 diabetes, to improve glucose control, to reduce the risk of major cardiovascular events in those who also have established heart disease, and, since January 2025, to slow kidney disease progression in those with chronic kidney disease. Those indications trace back to SUSTAIN-6 and FLOW.

Wegovy is approved for chronic weight management in adults and adolescents with obesity, or overweight with a weight-related condition, and since March 2024 to reduce cardiovascular risk in adults with established heart disease and overweight or obesity. Those indications rest on the STEP trials and SELECT.

This matters when interpreting the blood pressure numbers. The larger systolic reductions came from Wegovy trials, in people who lost more weight. The Ozempic trials showed smaller changes in people with diabetes whose pressure was already treated. Quoting a STEP figure to describe what Ozempic does for blood pressure is a common shortcut, and not quite accurate.

Two related products deserve a sentence each. Rybelsus is an oral tablet form of semaglutide for type 2 diabetes; a dedicated outcome trial published in 2025 reported a 14 percent reduction in major cardiovascular events. And compounded semaglutide, made by pharmacies rather than the manufacturer, is not FDA-approved, has not been reviewed for safety or effectiveness, and was not used in any of these trials. It is not for self-use.

Using Ozempic for weight loss in someone without diabetes is off-label. The evidence for such use is borrowed from the Wegovy trials, and whether it is appropriate for any individual is a judgment that belongs to the treating clinician.

Common myths about Ozempic and blood pressure, corrected

Viral claims tend to take a true finding and stretch it. Here are the stretches circulating most widely, each set beside what the trials support.

Myth: Ozempic can replace blood pressure medicine. The trials recorded a systolic drop of a few mmHg, roughly a third of what one antihypertensive medicine delivers, and most participants stayed on their existing blood pressure treatment throughout. Nothing in the data supports swapping one for the other.

Myth: it works like a statin. LDL cholesterol fell by about 3 percent in STEP 1 and by a similar sliver in SELECT. Statins lower LDL by 30–50 percent. The lipid that semaglutide does move substantially is triglycerides, which is a different target.

Myth: everyone who takes it gets heart protection. The outcome benefit was demonstrated in people with type 2 diabetes and heart disease, and in people with heart disease plus overweight or obesity. Whether it protects people with no cardiovascular history has not been tested in an outcome trial.

Myth: if your home readings fall, you should drop a pill yourself. Lower readings are useful information for the clinician who prescribed the blood pressure medicine. Stopping or reducing it independently can cause rebound hypertension and, with some medicines, withdrawal effects.

Myth: the heart benefit is entirely explained by weight loss. Possibly, but the early separation of event curves and the sharp fall in inflammation markers suggest more may be involved. The honest answer is that nobody knows the proportions yet.

Myth: compounded versions give the same results. No compounded product was studied in any of these trials, and such products are not FDA-approved. Results from SELECT or SUSTAIN-6 cannot be transferred to them.

Each correction points the same way: the real findings are good enough not to need embellishment.

When to see a doctor: red flags on Ozempic

Most people on semaglutide need routine follow-up rather than urgent care, but a short list of symptoms should not wait. Treat the first group as emergencies and call emergency services.

• Chest pain, pressure or tightness, especially with breathlessness, sweating or pain spreading to the arm or jaw.
• Sudden weakness or numbness on one side, drooping of the face, slurred speech or sudden confusion.
• Fainting, or dizziness so severe that standing is unsafe.
• Severe, persistent abdominal pain, particularly if it bores through to the back and comes with vomiting; this can signal pancreatitis.

The second group warrants a same-day or next-day call to the prescribing clinician.

• Repeated home blood pressure readings below about 90/60 with lightheadedness, or above 180/120 on more than one occasion.
• Vomiting or diarrhea lasting more than a day, inability to keep fluids down, very dark urine or passing very little urine; dehydration can lower blood pressure and injure the kidneys.
• Pain in the upper right abdomen, fever, yellowing of the skin or eyes, or pale stools, which can point to gallbladder trouble.
• A persistently racing or pounding heartbeat at rest, or palpitations with breathlessness.
• New blurring or changes in vision, especially in someone with diabetes.
• Shaking, sweating, confusion or hunger that suggests low blood sugar, particularly if insulin or a sulfonylurea is also prescribed.
• A lump or swelling in the neck, hoarseness that does not resolve, or trouble swallowing.

Alongside the red flags, the ordinary rhythm of care matters: blood pressure, kidney function and lipids checked before starting and at the intervals the clinician sets, and a home blood pressure log brought to each visit. Every decision about starting, continuing, adjusting or stopping semaglutide, or any medicine taken alongside it, rests with the prescribing clinician. This article is background for that conversation, not a replacement for it.

Already on blood pressure or cholesterol medicine? What to discuss with your clinician

Many people prescribed semaglutide are already taking a statin, an antihypertensive or both, which is exactly the profile the outcome trials enrolled. The practical question is not whether to keep those medicines but how the new one changes the monitoring around them.

Start with the home log. Readings taken at the same times each day for a couple of weeks, recorded with the date, give the clinician a far better picture than a single office number. If systolic pressure has fallen into a range that produces lightheadedness, the clinician may consider adjusting antihypertensive treatment. That is their call, and it is made with the whole picture, including kidney function, in view.

Hydration deserves a specific conversation. Early gastrointestinal effects can reduce fluid intake, and some blood pressure medicines, particularly diuretics and those acting on the kidney’s renin-angiotensin system, become riskier when a person is dehydrated. Clinicians often give advice on what to do on days when eating and drinking are difficult. Ask for it in advance.

On cholesterol, the message is simpler. Semaglutide does not do the job a statin does, so an LDL target that was set before starting it remains the target afterward. Expect triglycerides to improve on the next lipid panel; do not expect LDL to move much. Anyone whose statin was prescribed after a heart attack or stroke has particularly strong evidence behind continuing it.

Glucose medicines may also need review as weight falls, since insulin requirements often drop. That, again, is a prescriber’s decision, made on the basis of readings rather than guesswork.

The through-line is that semaglutide fits into existing cardiometabolic care rather than displacing it. The trials that made the headlines were conducted on top of standard treatment, and their results describe what happens when the medicine is added, not when something else is taken away.

Frequently asked questions

Does Ozempic lower blood pressure?

Yes, modestly. In SUSTAIN-6, the outcome trial in people with type 2 diabetes, systolic blood pressure fell by roughly 1–3 mmHg compared with placebo; trials of the higher-strength formulation in people with obesity found reductions closer to 4–5 mmHg. Diastolic pressure changed very little. The effect is real but small, and it was measured in people who mostly continued their existing blood pressure treatment.

How much does Ozempic lower blood pressure compared with a blood pressure pill?

Roughly a third as much. A single antihypertensive medicine typically lowers systolic pressure by about 9 mmHg, while semaglutide trials recorded reductions of about 2–5 mmHg versus placebo. The effect is similar in size to regular aerobic exercise or reducing dietary sodium. It adds to, rather than replaces, standard blood pressure treatment, and any adjustment to prescribed medicines belongs to the clinician managing them.

Does Ozempic lower cholesterol? What the trials show about ozempic and cholesterol

It barely moves LDL cholesterol but substantially lowers triglycerides. In STEP 1, LDL and total cholesterol fell by about 3 percent more than placebo, a change too small to matter clinically; statins lower LDL by 30–50 percent. Triglycerides fell by about 22 percent in STEP 1 and about 18 percent in SELECT. HDL rose slightly. Anyone with an LDL target should expect to keep their cholesterol medicine.

Can Ozempic replace my blood pressure medication?

No. The trials show a blood pressure effect far smaller than that of an antihypertensive medicine, and participants kept taking their existing treatment throughout. Stopping or reducing a blood pressure medicine on your own can cause rebound high blood pressure and other problems. If home readings fall after starting semaglutide, record them and bring the log to the clinician who prescribed the blood pressure medicine; only they should decide on changes.

Does Ozempic raise heart rate?

Yes, slightly. Across the semaglutide trials, resting heart rate increased by roughly 2–4 beats per minute compared with placebo. The mechanism is not fully understood, and in SUSTAIN-6 and SELECT the increase was not associated with more cardiac events. A persistently racing or pounding heartbeat at rest, or palpitations with breathlessness, should still be reported to the prescribing clinician promptly.

Is Ozempic approved to protect the heart?

Yes, in a defined group. Since January 2020 the Ozempic label has included reducing the risk of major cardiovascular events in adults with type 2 diabetes and established cardiovascular disease, based on SUSTAIN-6. Since January 2025 it also covers slowing kidney disease in adults with type 2 diabetes and chronic kidney disease. The cardiovascular indication for people without diabetes belongs to Wegovy, based on SELECT.

Why did the SELECT trial use Wegovy rather than Ozempic?

Because SELECT studied people with heart disease and overweight or obesity but no diabetes, the population Wegovy is approved for. The molecule, semaglutide, is identical in both products, but the strengths and labeled uses differ. SELECT’s blood pressure reduction of about 3.8 mmHg and its 20 percent fall in cardiovascular events therefore describe Wegovy’s trial population, not the diabetes population studied in Ozempic’s own trials.

Can Ozempic cause low blood pressure?

Directly, rarely; indirectly, yes. The medicine’s own blood pressure effect is small, but early nausea and vomiting can lead to dehydration, which lowers blood pressure, causes dizziness on standing and can stress the kidneys. The risk is higher for people also taking diuretics or certain other antihypertensives. Persistent vomiting, very dark urine, fainting or repeated readings below about 90/60 with symptoms warrant a prompt call to the clinician.

Is the heart benefit from Ozempic just because of weight loss?

Nobody knows the proportions yet. In SELECT the event curves separated within months, before most weight was lost, and the inflammation marker hsCRP fell by about 38 percent, more than weight loss alone would predict. Those findings come from secondary analyses, which can suggest but not prove a direct effect. Most researchers suspect a combination of weight-related and direct vascular mechanisms.

What happens to blood pressure if I stop Ozempic?

The evidence suggests the benefit fades. Trial extensions and observational reports show weight tends to return after semaglutide is stopped, and blood pressure appears to drift back with it, consistent with an effect that depends on continued use. There is no trial evidence that the medicine permanently resets blood pressure. Any decision to stop should be made with the prescribing clinician, who can plan monitoring.

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.